ACHFF (Arch Biopartners) EPS (Basic): $-0.04 (TTM As of Mar. 2026)


ACHFF Arch Biopartners Inc ACHFF
26 GF Score
Price $0.64
! 4 Warning Signs
View Full Analysis

What is Arch Biopartners EPS (Basic)?

Arch Biopartners ACHFF +5.30% 26 EPS (Basic) is $-0.04 as of Mar. 2026. GuruFocus rates ACHFF with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Arch Biopartners's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.04.

Arch Biopartners's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.04.

Arch Biopartners's EPS without NRI for the three months ended in Mar. 2026 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Arch Biopartners  (OTCPK:ACHFF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Arch Biopartners EPS (Basic) Related Terms

Arch Biopartners EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Arch Biopartners's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Biopartners EPS (Basic) Chart

Arch Biopartners Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.02 -0.04 -0.05 -0.02

Arch Biopartners Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.00 -0.01 -0.02 -0.01
ACHFF
26GF Score
Arch Biopartners Inc ACHFF
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Biopartners EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Arch Biopartners's Basic EPS for the fiscal year that ended in Sep. 2025 is calculated as

Basic EPS (A: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.123-0)/65.604
=-0.02

Arch Biopartners's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.38-0)/66.939
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.04 mean?
Arch Biopartners (ACHFF) has a EPS (Basic) of $-0.04 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Arch Biopartners and its competitors.
Is Arch Biopartners' EPS (Basic) too high?
Arch Biopartners' current EPS (Basic) is $-0.04. Overall, Arch Biopartners has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Arch Biopartners' EPS (Basic) compare to VRTX and REGN?
Arch Biopartners' EPS (Basic) of $-0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Arch Biopartners and its competitors. Arch Biopartners's current EPS (Basic) is $-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Biopartners stock overvalued right now?
Arch Biopartners (ACHFF) has a current EPS (Basic) of $-0.04. The current EPS (Basic) is $-0.04. Arch Biopartners' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Arch Biopartners (ACHFF), the current EPS (Basic) is $-0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Biopartners Business Description

Other Exchanges 8HA:GermanyARCH:Canada
Address 545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic kidney conditions to benefit from novel, targeted therapies that address unmet medical needs in kidney care.
26GF Score

Get the complete analysis for ACHFF

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price